| 引用本文: | 陈月圆, 黄永林, 陈洁晶, 卢凤来, 李典鹏.醉鱼草苷Ⅳ对H22肝癌小鼠的抑瘤作用[J].广西植物,2014,(5):710-713.[点击复制] |
| CHEN Yue-Yuan, HUANG Yong-Lin, CHEN Jie-Jing,
LU Feng-Lai, LI Dian-Peng.Inhibitory effect of buddlejasaponin Ⅳ on hepatocarcinoma 22(H22)in mice[J].Guihaia,2014,(5):710-713.[点击复制] |
|
| |
|
|
| 本文已被：浏览 4117次 下载 1561次 |
码上扫一扫！ |
|
|
| 醉鱼草苷Ⅳ对H22肝癌小鼠的抑瘤作用 |
|
陈月圆1, 黄永林1, 陈洁晶2, 卢凤来1, 李典鹏1*
|
|
1. 广西植物功能物质研究与利用重点实验室, 广西植物研究所, 广西 桂林 541006;2. 广西代谢性疾病研究重点实验室, 广西 桂林 541002
|
|
| 摘要: |
| 为观察醉鱼草苷Ⅳ对H22肝癌小鼠的体内抑瘤作用,取H22肝癌细胞接种于小鼠右腋皮下,H22肝癌小鼠随机分为5组:模型组、醉鱼草苷Ⅳ高、中、低(1.00、0.50、0.25 mg/kg)3个剂量组和阳性药(CTX,20.0 mg/kg)对照组。每组10只,治疗期间记录各组小鼠的体重变化并观察小鼠生存状态,连续腹腔注射10 d后,于第11天观测抑瘤率、脾腺指数、胸腺指数,同时进行血清中SOD、MDA、GGT和AKP含量检测。结果表明:与模型组比较,醉鱼草苷Ⅳ高、中剂量组对小鼠H22移植性肝癌均有显著的抑瘤作用(P<0.01),抑瘤率分别为56.96%和50.63%; 与模型组相比,醉鱼草苷Ⅳ高剂量组小鼠血清SOD活性增加(P<0.05),醉鱼草苷Ⅳ各剂量组血清MDA、GGT和AKP水平均降低(P<0.01); 除SOD活性之外,环磷酰胺组与模型组比较无显著差异。说明醉鱼草苷Ⅳ在体内具有抗肝癌作用,其机理可能和机体的抗氧化能力有关,有待于进一步研究 |
| 关键词: 醉鱼草苷Ⅳ H22肝癌 抑瘤率 |
| DOI：10.3969/j.issn.1000-3142.2014.05.023 |
| 分类号:Q946; R73-36 |
| 基金项目: |
|
| Inhibitory effect of buddlejasaponin Ⅳ on hepatocarcinoma 22(H22)in mice |
|
CHEN Yue-Yuan1, HUANG Yong-Lin1, CHEN Jie-Jing2,
LU Feng-Lai1, LI Dian-Peng1*
|
|
1. Guangxi Key Laboratory of Functional Phytochemicals Research and Utilization, Guangxi Institute of Botany,
Guilin 541006, China;2. Guangxi Key Laboratory of Metabolic Diseases Research, Guilin 541002, China
1. Guangxi Key Laboratory of Functional Phytochemicals Research and Utilization, Guangxi Institute of Botany,
Guilin 541006, China; 2. Guangxi Key Laboratory of Metabolic Diseases Research, Guilin 541002, China
|
| Abstract: |
| To observe the inhibitory effect of buddlejasaponin Ⅳ on tumor growth on murine transplanted hepatocarcinoma 22(H22)in vivo,tumor inhibitory activities were tested in experimental tumor H22 mice. The tumor bearing mice were randomly divided into control group,CTX group(CTX,20.0 mg/kg)and buddlejasaponin Ⅳ treatment groups(1.00,0.50,0.25 mg/kg). The body weight and survival of mice in all groups were recorded. After exposing to medications for 10 days,all the mice were killed on second day,the tumors were taken out and weighted with tumor inhibition rate,and the indexes of spleen and thymus were checked,and the SOD activity,MDA,GGT and AKP levels in serum in each group were detected. The results showed that the high and middle dosage buddlejasaponin Ⅳ treated groups could inhibit H22 growth compared with the control group(P<0.01),the inhibitory rate was 56.96%,50.63% respectively. In the high dosage buddlejasaponin Ⅳ treated groups,the activity of serum SOD increased(P<0.05),and in all the buddlejasaponin Ⅳ treated groups,serum MDA contents decreased(P<0.01). Compared with the control group,in all the buddlejasaponin Ⅳ treated groups,serum GGT,AKP content compared were highly significant differences(P<0.01),while the CTX group showed no significant difference. Buddlejasaponin Ⅳ can inhibit hepatocarcinoma growth. The mechanism may regulate the body antioxidant capacity,and needs further study. |
| Key words: buddlejasaponin Ⅳ hepatocarcinoma 22 tumor inhibitory rate |
|
|
|
|
|
